OnePin Peptide Library · Weight
Tesofensine
NS-2330
Tesofensine is a small-molecule monoamine reuptake inhibitor (norepinephrine, serotonin, dopamine triple reuptake inhibitor / SNRI+DRI). Originally developed by NeuroSearch for Parkinson's disease and Alzheimer's disease, repurposed for obesity after Phase 2 trials showed substantial weight loss as an off-target effect. The TIPO-1 trial in obese patients showed dose-dependent weight loss up to ~12% at 1mg daily over 24 weeks - among the largest non-injectable weight loss agents.
Morning preferred (CNS-active).
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Tesofensine is a triple monoamine reuptake inhibitor:
Norepinephrine Reuptake Inhibition
Increases synaptic NE - drives sympathetic activation, energy expenditure, and appetite suppression.
Dopamine Reuptake Inhibition
Increases synaptic DA in reward and appetite circuits - reduces hedonic feeding drive.
Serotonin Reuptake Inhibition
Modest 5-HT effect contributes to appetite suppression and satiety.
Net Effect
Substantial appetite reduction + modest energy expenditure increase = up to 12% weight loss at 1mg daily in TIPO-1 trial.
Cardiovascular Side Effects
NE/DA reuptake inhibition raises HR and BP - dose-limiting at higher doses. Tesomet combination with metoprolol (beta-blocker) mitigates this in Mexican formulation.
CNS Side Effects
Insomnia, dry mouth, nausea, anxiety - all class-typical for triple reuptake inhibitors.
What to expect
Days 1-7: rapid appetite suppression onset.
Weeks 4-12: peak weight loss (up to ~12% at 1mg).
Long-term: efficacy beyond 24 weeks not well characterized.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Side effects & safety
Commonly reported
- Dry mouth
- Insomnia
- Nausea
- Anxiety
- Elevated heart rate
- Mild blood pressure elevation
Less common & notes
- Severe tachycardia, hypertension.
- Mood/psychiatric effects (mania-like in susceptible).
- Long-term safety beyond 24 weeks limited.
- Cardiovascular events at higher doses are the primary concern.
Pharmacokinetics
Storage. Capsule. Cool dry location.
Regulatory status
Approved in Mexico (Tesomet, 2023) for obesity and Prader-Willi syndrome. NOT FDA-approved. Available outside Mexico as research chemical.
Put it to work
Calculate, log & track
Open Tesofensine straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Tesofensine in the app →Go deeper
The guide & community
The complete Tesofensine walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗